Australia Health

Sigma Healthcare (ASX:SIG) reported full-year revenue of $10.8 billion and normalised EBIT of $1.09 billion for the period ended June 30.

Ramsay Health Care (ASX:RHC) reported a full-year net profit after tax of $329.2 million for the twelve months ended June 30.

Neuren Pharmaceuticals (ASX:NEU) declared a fully franked interim dividend of 15 cents per share for H1 2026.

PolyNovo (ASX:PNV) generated total revenue of $150 million for the year ended June 30, marking a 16.1% increase.

Neuren Pharmaceuticals (ASX:NEU) secured European Commission marketing authorisation for DAYBU (trofinetide).

Nanosonics (ASX:NAN) increased its annual revenue by 3% to $203.9 million for the financial year ended June 30.

Integral Diagnostics (ASX:IDX) announced its financial results for the year ended June 30, delivering an operating net profit after tax of $47.4 million.

Cyclopharm (ASX:CYC) delivered a record $17.5 million in revenue for the six months ended June 30.

Regis Healthcare (ASX:REG) announced a full-year revenue increase to $1.35 billion alongside an underlying EBITDA of $138 million.

Reece (ASX:REH) increased its FY26 sales revenue by 4.5% to $9.38 billion.

Fisher & Paykel Healthcare (ASX:FPH) increased its 2027 profit guidance to $525–565 million, citing strong hardware demand.

Telix Pharmaceuticals (ASX:TLX) reported group revenue of US$477 million for the first half of 2026.